Kawamura Kazunori, Kubota Kazuo, Kobayashi Tadayuki, Elsinga Philip H, Ono Mayumi, Maeda Minoru, Ishiwata Kiichi
Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Naka-cho 1-1, Itabashi-ku, Tokyo 173-0022, Japan.
Ann Nucl Med. 2005 Dec;19(8):701-9. doi: 10.1007/BF02985120.
Sigma receptors are expressed in a wide variety of tumor cell lines, and are expressed in proliferating cells. A radioligand for the visualization of sigma receptors could be useful for selective detection of primary tumors and their metastases, and for non-invasive assessment of tumor proliferative status. To this end we evaluated two sigma receptor ligands, [11C]SA5845 and [11C]SA4503. In an in vitro study, AH109A hepatoma showed moderate densities of sigma1 and sigma2 receptors, and VX-2 carcinoma showed a high density of sigma2 receptors: Bmax (fmol/mg protein) for sigma1 vs. sigma2, 1,700 vs. 1,200 for AH109A hepatoma and 800 vs. 10,000 for VX-2 carcinoma. In a cell growth assay in vitro, neither SA5845 nor SA4503 (<10 microM) showed any inhibitory effect on proliferation of the AH109A hepatoma cells. In rats, the uptake of [11C]SA5845 and [11C]SA4503 in AH109A tissues was accumulated over the first 60 minutes; however, the uptake of both tracers increased by co-injection with haloperidol as a sigma receptor ligand. On the other hand, in the PET studies of rabbits, the uptake of [11C]SA5845 in the VX-2 carcinoma was relatively higher than that of [11C]SA4503, because of a much higher density of sigma2 receptors compared to sigma1 receptors in the VX-2 tissue, and the uptake of both tracers in the VX-2 tissue was decreased by carrier-loading and pre-treatment with haloperidol ([11C]SA5845, 53% and 26%, respectively; [11C]SA4503, 41% and 22%, respectively at 30 minutes after injection). Therefore, [11C]SA5845 and [11C]SA4503 may be potential ligands for PET imaging of sigma receptor-rich tumors.
σ受体在多种肿瘤细胞系中表达,并在增殖细胞中表达。用于可视化σ受体的放射性配体可能有助于原发性肿瘤及其转移灶的选择性检测,以及肿瘤增殖状态的无创评估。为此,我们评估了两种σ受体配体,[11C]SA5845和[11C]SA4503。在一项体外研究中,AH109A肝癌显示出中等密度的σ1和σ2受体,VX-2癌显示出高密度的σ2受体:AH109A肝癌的σ1与σ2的Bmax(fmol/mg蛋白)分别为1700和1200,VX-2癌为800和10000。在体外细胞生长试验中,SA5845和SA4503(<10μM)均未对AH109A肝癌细胞的增殖显示出任何抑制作用。在大鼠中,[11C]SA5845和[11C]SA4503在AH109A组织中的摄取在最初60分钟内积累;然而,作为σ受体配体与氟哌啶醇共同注射时,两种示踪剂的摄取均增加。另一方面,在兔的PET研究中,[11C]SA5845在VX-2癌中的摄取相对高于[11C]SA4503,这是因为VX-2组织中σ2受体的密度比σ1受体高得多,并且通过载体负载和氟哌啶醇预处理后,VX-2组织中两种示踪剂的摄取均降低([11C]SA5845分别在注射后30分钟时降低53%和26%;[11C]SA4503分别降低41%和22%)。因此,[11C]SA5845和[11C]SA4503可能是富含σ受体肿瘤PET成像的潜在配体。